Investment Rating - The report assigns a "Strong Buy" rating for SF Holding (06936.HK) with an expected target price of 54.50 HKD, indicating a potential upside of 44% from the current price of 37.75 HKD [4][8]. Core Insights - The report emphasizes the sustainable improvement in net profit margins for the company, driven by resilient demand in core express delivery services and a strategic shift from product sales to industry solution offerings [1][2]. - The company is expected to achieve a revenue growth of over 20% in logistics income from e-commerce, telecommunications, automotive, and industrial manufacturing sectors in 2024 [1]. - The operational transformation aimed at cost reduction is based on a new operational model that has reduced the average distance for delivery personnel by 38% [2]. - The international business segment is projected to experience a profit increase, with significant growth in air cargo throughput at Ezhou Airport [2][8]. Financial Performance - In 2024, the company reported total revenue of 284.42 billion RMB, a year-on-year increase of 10.1%, with net profit reaching 10.17 billion RMB, up 23.5% [8]. - The net profit margin for 2024 was recorded at 3.6%, reflecting a 0.4% increase from the previous year [8]. - The company plans to distribute a cash dividend of 4.104 billion RMB for 2024, representing a 40% payout ratio [8]. Business Growth - The express delivery business volume is expected to grow by 11.8% year-on-year, with a revenue of 122.21 billion RMB in 2024, marking a 5.8% increase [1][8]. - The company has outperformed its peers in terms of business volume growth in March 2025, with a growth rate of 25.4% [8]. Valuation Metrics - The report maintains profit forecasts for 2025-2027, with expected net profits of 11.7 billion RMB, 13.7 billion RMB, and 15.6 billion RMB respectively, corresponding to EPS of 2.3, 2.7, and 3.1 RMB [8]. - The projected price-to-earnings (P/E) ratios for the next three years are 15, 13, and 11 times [8].

中国有色矿业（1258.HK）2024 年年报&2025 年一季报点评 历史最佳年度归母净利，期待自产铜持续增长 2025 年 04 月 26 日 [Table_Author] 分析师：邱祖学 分析师：张弋清 执业证号：S0100521120001 执业证号：S0100523100001 邮箱：qiuzuxue@mszq.com 邮箱：zhangyiqing@mszq.com ➢ 事件：2025 年 4 月 25 日，公司发布 2024 年年报和 2025 年一季报。2024 年公司实现营收 38.17 亿美元，同比增长 5.8%，实现归母净利润 3.99 亿美元， 同比增长 43.6%。单季度看，2024Q4 公司实现归母净利润 0.85 亿美元，同比 增长 273.9%，环比减少 11.1%；2025Q1 公司实现归母净利润 1.23 亿美元，同 比增长 46%，环比增长 46%。25Q1 业绩超市场预期。 ➢ 2024 年归母净利润创历史最佳，主要得益于铜价上涨。 ➢ 2025 年一季度公司归母净利润同环比均大幅提升，主要得益于铜价上涨以 及铜产量恢复正常。 ① 产量： 2025Q1 公 司 粗 铜 及 ...

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 绿源集团控股(2451.HK) 投资评级 上次评级 [Table_Author] 姜文镪 新消费行业首席分析师 执业编号：S1500524120004 邮 箱： jiangwenqiang@cindasc.com 骆峥 轻工制造行业分析师 执业编号：S1500525020001 邮 箱： luozheng1@cindasc.com 邓健全 汽车行业首席分析师 执业编号：S1500525010002 邮 箱： dengjianquan@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 绿源集团控股：电动两轮车稳健增长，积极布 局新成长曲线 [Table_ReportDate] 2025 年 4 月 26 日 [Table_S 事件：公司发布 ummary] 2024 年年报。24 年公司实现收入 50.72 亿元（-0.2%）， 归母净利润 1.17 亿 ...

中国有色矿业（1258.HK）2024 年年报&2025 年一季报点评 历史最佳年度归母净利，期待自产铜持续增长 2025 年 04 月 26 日 [Table_Author] 分析师：邱祖学 分析师：张弋清 执业证号：S0100521120001 执业证号：S0100523100001 邮箱：qiuzuxue@mszq.com 邮箱：zhangyiqing@mszq.com ➢ 事件：2025 年 4 月 25 日，公司发布 2024 年年报和 2025 年一季报。2024 年公司实现营收 38.17 亿美元，同比增长 5.8%，实现归母净利润 3.99 亿美元， 同比增长 43.6%。单季度看，2024Q4 公司实现归母净利润 0.85 亿美元，同比 增长 273.9%，环比减少 11.1%；2025Q1 公司实现归母净利润 1.23 亿美元，同 比增长 46%，环比增长 46%。25Q1 业绩超市场预期。 ➢ 2024 年归母净利润创历史最佳，主要得益于铜价上涨。 ➢ 2025 年一季度公司归母净利润同环比均大幅提升，主要得益于铜价上涨以 及铜产量恢复正常。 ① 产量： 2025Q1 公 司 粗 铜 及 ...

Investment Rating - The report maintains a "Buy" rating for the company with a target price not specified [5] Core Views - The company reported FY25Q3 revenue of $1.2 billion, a decrease of 2% year-over-year, with Non-GAAP operating profit at $140 million, down 0.2%, and Non-GAAP net profit attributable to shareholders at $110 million, down 14% [1] - Excluding self-operated products and live e-commerce, revenue grew by 21.2% this quarter, with overseas exam preparation and consulting revenues increasing by approximately 7.1% and 21.4%, respectively [2] - The company is focusing on sustainable long-term growth by enhancing product quality and operational efficiency, while also integrating innovative technologies into its educational offerings [2][3] Financial Performance Summary - The Non-GAAP operating profit margin for the quarter was 13.3%, down from 15.1% in the same period last year, impacted by slower growth in overseas business and investments in newly integrated cultural tourism operations [3] - The company has adjusted its revenue forecasts for FY25-27 to $4.9 billion, $5.8 billion, and $6.8 billion, respectively, with Non-GAAP net profits projected at $460 million, $570 million, and $690 million [4]

证券研究报告 公司研究 [Table_ReportType] 公司点评报告 [Table_StockAndRank] 绿源集团控股(2451.HK) 投资评级 上次评级 [Table_Author] 姜文镪 新消费行业首席分析师 执业编号：S1500524120004 邮 箱： jiangwenqiang@cindasc.com 骆峥 轻工制造行业分析师 执业编号：S1500525020001 邮 箱： luozheng1@cindasc.com 邓健全 汽车行业首席分析师 执业编号：S1500525010002 邮 箱： dengjianquan@cindasc.com 信达证券股份有限公司 CINDA SECURITIES CO.,LTD 北京市西城区宣武门西大街甲127号金隅大厦B 座 邮编：100031 [Table_Title] 绿源集团控股：电动两轮车稳健增长，积极布 局新成长曲线 [Table_ReportDate] 2025 年 4 月 26 日 [Table_S 事件：公司发布 ummary] 2024 年年报。24 年公司实现收入 50.72 亿元（-0.2%）， 归母净利润 1.17 亿 ...

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [3][7]. Core Views - The company demonstrates stable profitability, low risk, and high dividends, with a current H-share dividend yield of approximately 5%, making it an attractive investment opportunity [7][9]. - The company has effectively managed real estate risks, maintaining strong asset quality and a robust provisioning base, which supports stable performance [6][9]. - The outlook for loan growth is optimistic, with targets set at 7%-8% for 2025, focusing on retail lending as a key growth area [6][8]. Financial Data and Profit Forecast - Revenue (in million) is projected to be 339,123 in 2023, with a slight decline in 2024 to 337,488, followed by a recovery to 344,327.10 in 2025, and further growth expected in subsequent years [2]. - Net profit attributable to shareholders is forecasted to grow from 146,602 in 2023 to 153,326.11 in 2025, reflecting a compound annual growth rate (CAGR) of approximately 3.3% [2][8]. - Earnings per share (EPS) is expected to increase from 5.63 in 2023 to 5.86 in 2025 [2]. Market Data - As of April 24, 2025, the closing price of the company's H-shares was 44.30 HKD, with a market capitalization of approximately 11,172.39 billion HKD [3]. - The company has outperformed the Wind Hong Kong Bank Index by 14 percentage points since early 2024, with a cumulative increase of 77.5% [6]. Key Assumptions - The company anticipates a net profit growth of 3.3%, 5.2%, and 9.6% for the years 2025 to 2027, respectively [8]. - Loan growth is expected to stabilize at 7.0% annually from 2025 to 2027, with a projected non-performing loan ratio of 0.94% during the same period [8]. Observations on Market Perception - The market has not fully recognized the company's unique "defensive and offensive" characteristics, which are expected to provide a safety net in uncertain times [9]. - The company has successfully navigated real estate risks, with a significant reduction in non-performing loans related to real estate, indicating a stable outlook for asset quality [9]. Catalysts for Stock Performance - Key catalysts for stock performance include effective policy implementation, better-than-expected retail recovery, and sustained improvement in real estate sales [10].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1][5][8] Core Views - The company is experiencing short-term performance pressure but is actively positioning itself in core cities [1][5] - Despite a cooling real estate market, the company reported a revenue increase of 20.7% year-on-year for 2024, reaching approximately RMB 158.55 billion [5] - The company's net profit attributable to shareholders for 2024 was RMB 1.60 billion, a decrease of 48.8% compared to 2023 [5] - The company has focused on acquiring land in core cities, with 92% of its new saleable value located in first and second-tier cities [5] - The average financing cost has decreased to 3.7%, down from 4.1% in 2023, indicating improved debt management [5] Financial Performance Summary - Revenue for 2023 was RMB 131.95 billion, with a projected decline to RMB 152.99 billion in 2025, reflecting a -4% year-on-year growth rate [1] - The net profit for 2023 was RMB 3.09 billion, with a forecasted increase to RMB 2.55 billion by 2027 [1] - Earnings per share (EPS) are projected to be RMB 0.74 in 2025, RMB 0.86 in 2026, and RMB 1.00 in 2027 [1][5] - The company's price-to-earnings (P/E) ratio is expected to decrease from 15.5 in 2024 to 9.7 by 2027 [1][5] Market Positioning - The company has maintained a strong sales performance, with a sales area of 14.09 million square meters in 2024, despite an 8.9% year-on-year decline [5] - The company has successfully launched 42 new projects in 2024, with a total saleable value of approximately RMB 108.8 billion [5] - The company’s gross margin for 2024 was reported at 12.76%, a slight decrease from the previous year [5]

Investment Rating - The investment rating for the company is "Buy" [4] Core Views - The company is expected to see rapid growth in adjusted profits in 2024, with business development (BD) achievements highlighting its innovative capabilities, leading to potential valuation increases [1][2] - The company reported a revenue of 6.635 billion RMB in 2024, a year-over-year increase of 0.4%, and an adjusted net profit of approximately 1.018 billion RMB, reflecting a year-over-year growth of 41.6% [1][2] - The innovative drug segment is projected to continue its upward trend, with revenues from innovative drugs reaching 4.928 billion RMB in 2024, accounting for 74.3% of total revenue [2] Summary by Sections Performance - In 2024, the company achieved a group revenue of 6.635 billion RMB and a net profit of 733 million RMB, with an adjusted net profit of approximately 1.018 billion RMB [1] - The company has made significant progress with multiple innovative drugs, including the approval of two new drugs and the acceptance of three new drug NDAs [1] Innovation - The revenue from innovative drugs is expected to grow, driven by existing products and new launches, maintaining a high growth rate [2] - The partnership with AbbVie for the licensing of a new candidate drug demonstrates the strength of the company's innovation platform [2] Earnings Forecast and Valuation - The earnings per share (EPS) forecast for 2025-2027 is projected to be 0.43, 0.55, and 0.63 RMB, respectively, with a price-to-earnings (P/E) ratio of 19 times based on the closing price on April 24, 2025 [3] - The company is expected to maintain rapid growth in performance driven by both existing and new innovative drug products [3]

Investment Rating - The report maintains a "Strong Buy" rating for the company, with a target price of 210 HKD [1][7]. Core Insights - The company reported a significant revenue growth of 165%-170% year-on-year for Q1 2025, exceeding previous guidance of 100%. The growth was driven by strong performance in both domestic and international markets, with notable increases in online and offline channels [1][7]. - The company is undergoing a comprehensive upgrade of its IP ecosystem, aiming to transition from a trendy toy brand to a broader entertainment giant. This includes collaborations with high-profile celebrities and the launch of new product lines [7]. - The organization is implementing a global restructuring to enhance operational efficiency and support its expansion strategy, establishing regional headquarters across major markets [7]. Financial Summary - Total revenue is projected to reach 24,825 million HKD in 2025, with a year-on-year growth rate of 90.4%. By 2027, revenue is expected to grow to 43,480 million HKD [3][8]. - The net profit attributable to shareholders is forecasted to be 6,249 million HKD in 2025, reflecting a growth rate of 99.9%, and is expected to reach 11,781 million HKD by 2027 [3][8]. - The earnings per share (EPS) is estimated to be 4.65 HKD in 2025, increasing to 8.77 HKD by 2027 [3][8]. Market Performance - The company has shown exceptional growth in overseas markets, with revenue increases of 475%-480% year-on-year, particularly strong in the Americas and Europe [1][7]. - The company is leveraging its IP to penetrate luxury markets, with successful collaborations and product launches that resonate with consumers [7]. Strategic Outlook - The company is expected to continue its momentum with new product launches and a focus on multi-category expansion, including card games and accessories, while enhancing its IP content [7]. - The restructuring aims to optimize operations and support the company's goal of becoming a global consumer goods group centered around its IP [7].